Developer docs
API playgroundTry for free, no card

Search company profiles

LTT Bio-Pharma

Full company profile

uuid000mv8e

Namestring
LTT Bio-Pharma
Legal namestring
株式会社LTTバイオファーマ
Websiteurl
ltt.co.jp
Company typeenum
Private
Founded yearint
2003
Descriptiontext

LTT Bio-Pharma Co., Ltd. (株式会社LTTバイオファーマ) is a privately held Japanese drug discovery bio-venture founded in 1988 (spun off into its current legal form in 2003), headquartered in Tokyo with a research center at Shonan Health Innovation Park in Fujisawa. The company operates two proprietary technology platforms: Drug Repositioning (DR), supported by a proprietary library of 1,000+ approved drugs used for indication screening, and Drug Delivery System (DDS), encompassing world-first lecithinization technology (commercialized as PC-SOD), world-first stealth-type nanoparticles combining targeting and sustained release, and an established lipid emulsion DDS platform. Its marketed product family includes lipo-PGE1, lipo-NSAID, liposteroid, and transdermal steroid formulations licensed to major Japanese pharmaceutical partners and, in China, to Beijing Tide Pharmaceutical.

The company's pipeline of approximately 14 development candidates spans PC-SOD for CIPN/ARDS/myocardial infarction, LT-5001 in Phase III with Nobelpharma for trigeminal neuralgia, stealth-nanoparticle programs (Nano-PGE1, Nano-PGI2 derivative), and multiple DR-derived assets (LT-3001/3002/4001/4002/4010/4012) for COPD, dry eye, pulmonary fibrosis, and COVID-19 indications. Revenue is generated through four streams: licensing royalties and milestone payments (including from Beijing Tide for China and CKD for Korea), contract research and DR/DDS consultation services, joint development arrangements (e.g., LT-5001 with Nobelpharma; PC-SOD with Alfresa), and dividend income from the >11% equity stake in Beijing Tide Pharmaceutical. Distribution is entirely virtual: products are manufactured and commercialized by licensing partners.

LTT Bio-Pharma serves three primary customer segments: pharmaceutical companies seeking DR/DDS expertise and pipeline assets, Japanese academic institutions supported via DR Grant and PC-SOD Grant programs, and Japanese/Chinese medical companies needing cross-border licensing bridge services. The company maintains a capital and business alliance with Sino Biopharm (China's largest pharma group, 17%+ stake acquired via 2021 tender offer, renewed 2025) and operates a complex cross-shareholding with Beijing Tide Pharmaceutical (19%+ of LTT; 11%+ of Beijing Tide held by LTT). The company was listed on TSE Mothers in 2004, delisted in 2011, and is currently pursuing re-listing while reporting FY2025 net sales of ¥61.4 million against ¥5.26 billion in net assets and a 94.1% equity ratio.

Short descriptiontext

LTT Bio-Pharma is a Tokyo-based drug discovery bio-venture that uses proprietary Drug Repositioning and Drug Delivery System (DDS) technologies, including a 1,000+ approved drug library and world-first lecithinization and stealth-nanoparticle platforms, to develop and out-license pipeline assets to pharmaceutical partners in Japan, China, and increasingly Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug repositioning, drug delivery systems, pharmaceutical licensing, clinical drug development, lipid emulsion formulations
Industry2 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Drug Development
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing Revenue
TypeLicensing Royalties
Description

Revenue from licensing out pipeline assets (drug candidates at various development stages) to pharmaceutical companies. Some pipelines have progressed to Phase II clinical trials and are available for out-licensing. Also includes licensing fees from Beijing Tide Pharmaceutical for PC-SOD and AS-013 for the Chinese market, and CKD for Korean market.

ltt.co.jp
2Contract Research & Consultation
TypeProfessional Services
Description

Revenue from DR (drug repositioning) screening services, intellectual property consulting, and clinical trial bridging support provided to pharmaceutical companies and academic institutions. Includes DR grants to academia with funding up to 3 million yen per project.

ltt.co.jp
3Joint Development Revenue
TypeManaged Services
Description

Revenue from joint development arrangements where the company collaborates with partners on drug development, sharing costs and profits. Notable joint development with Nobelpharma Co., Ltd. since 2018 on LT-5001, and Alfresa Holdings on PC-SOD.

ltt.co.jp
4Dividend Income
TypeLicensing Royalties
Description

Dividend income from equity stakes in affiliated companies, primarily from Beijing Tide Pharmaceutical Co., Ltd. where LTT holds over 11% ownership.

ltt.co.jp
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details2 tiers
1DR Grant - Academic Research Support
ModelOtherBilling cadenceMulti-year contract
Notes

Subsidy limit: 3 million yen; Subsidy period: Up to 2 years from contract date. Library-only provision also available without research funding.

ltt.co.jp
2PC-SOD Grant - Academic Research Support
ModelOtherBilling cadenceMulti-year contract
Notes

Research funding and materials (PC-SOD) provided to selected researchers in Japan. PC-SOD-only provision without funding also available.

ltt.co.jp
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

LTT Bio-Pharma is a Tokyo-based drug discovery bio-venture that researches, develops, and commercializes pharmaceutical products using two proprietary technology platforms: Drug Repositioning (DR) and Drug Delivery Systems (DDS). The company has successfully launched multiple DDS-formulated products (Lipo-PGE1, Lipo-NSAID, liposteroid, and transdermal steroid formulations) through licensing partnerships with major Japanese and Chinese pharmaceutical companies, and maintains a pipeline of 14 drug candidates in clinical and preclinical development including PC-SOD and LT-5001.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • PC-SOD Phase II clinical trials showed efficacy in CIPN (chemotherapy-induced peripheral neuropathy) with statistical significance
+2 more records
Product overview1 text field

LTT Bio-Pharma is a drug discovery bio-venture company that has developed a portfolio of pharmaceutical products utilizing two core technology platforms: Drug Repositioning (DR) and Drug Delivery Systems (DDS). The company has successfully launched multiple DDS-based formulations including lipo-PGE1 products (Palux, Riple, Kaishi), lipo-steroids (Rimetasone, Farnesone, Farenerat, Haloart), and lipo-NSAIDs (Ropion, Kaifeng). Their pipeline includes PC-SOD (lecithinized SOD1) for CIPN and other indications, stealth-type nanoparticle products (NanoPGE1, Nano PGI2), and various DR-derived candidates (LT-3001, LT-3002, LT-4001, LT-4002, LT-4010, LT-4012, LT-5001). The company operates through collaborative R&D models with academia and pharmaceutical partners, leveraging their proprietary approved drug library and DDS technologies.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Beijing Tide Pharmaceutical Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2009-02-10
Description

Joint venture established in 1995 between LTT and China-Japan Friendship Hospital. LTT provides DDS technology and IP; Beijing Tide manufactures and sells DDS drugs in China. LTT holds 11%+ equity stake; Beijing Tide holds 19%+ of LTT shares. Joint R&D on PC-SOD and other pipelines. LTT acts as Beijing Tide's window for Japanese partnerships.

ltt.co.jp
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint development agreement since 2018 for LT-5001 drug (drug repositioning for existing drug). Companies jointly conduct clinical trials and share profits. Nobelpharma contributes high development success rate and regulatory expertise; LTT contributes DR technology. Phase III clinical trials ongoing for trigeminal neuralgia.

3Alfresa Holdings Corporation
Strategic tierCoreTypeStrategic or Co-development Partner
Description

PC-SOD joint development agreement concluded in 2025. Alfresa contributes to PC-SOD development for CIPN (chemotherapy-induced peripheral neuropathy) prevention/treatment.

ltt.co.jp
4Kansai Medical University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint research agreement signed April 2026 for drug discovery collaboration. Part of LTT's strategy to engage with academic institutions for pipeline development.

ltt.co.jp
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Contract research partner for DDS development. Collaborative research on stealth-type nanoparticle development using PLA (polylactic acid) technology.

6Musashino University (Faculty of Pharmacy)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborative DR research for pulmonary fibrosis treatment. Jointly screened approved drug library with LTT to discover LT-4010 for idiopathic pulmonary fibrosis.

ltt.co.jp
7Shujitsu University (Faculty of Pharmacy)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Contract research partner for drug development activities.

ltt.co.jp
8Aska Pharmaceutical Holdings Co., Ltd.
Strategic tierMinorTypeOthers
Description

DR consulting service agreement concluded 2021 for drug repositioning expertise and guidance.

ltt.co.jp
9ChongKunDang Pharm Corp (CKD)
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensed PC-SOD (inhalation formulation) for entire Korean territory in 2011.

10EA Pharma Co., Ltd.
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

License agreement signed 2015 for pipeline LT-4004.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1NanoCarrier
TypeDirect peer
Description

Japanese bio-venture specializing in micellar nanoparticle drug delivery technology for nucleic acid drugs and other therapeutics. Direct comparable as a small-cap Japanese DDS-focused biotech with similar licensing model.

TypeDirect peer
Description

Japanese specialty pharmaceutical company focused on niche therapeutic areas with in-licensing and co-development model. Similar size and venture-stage profile with comparable revenue/development stage.

3AnGes
TypeDirect peer
Description

Japanese bio-venture developing novel biologics and gene therapies, with similar late-stage clinical assets and licensing-driven business model. Comparable venture-stage bio-pharma with multiple pipeline candidates.

TypeBroad incumbent
Description

Japanese biopharmaceutical company with proprietary drug delivery technologies including J-Brain Cargo platform for CNS drug delivery. Larger established player with overlapping DDS expertise but broader portfolio.

5PeptiDream
TypeEmerging player
Description

Japanese bio-pharma with proprietary peptide discovery platform serving global pharma partners via licensing deals. Similar platform-based business model with global pharma licensing as core revenue driver.

6Mochida Pharmaceutical
TypeBroad incumbent
Description

Japanese specialty pharmaceutical company with focus on specialty pharma, regenerative medicine, and novel drug formulations. Larger incumbent with overlap in specialty pharmaceutical development.

7EPS Holdings
TypeOthers
Description

Japanese CRO and pharma services provider. Not a direct competitor but comparable as a Japan-listed pharma services/development company serving similar pharmaceutical customers.

TypeOthers
Description

Japan's largest CRO providing drug development services including clinical trial support. Comparable as Japanese pharma services/development ecosystem participant.

9Sosei Group Corporation
TypeEmerging player
Description

Japanese biotech with proprietary drug discovery platform (StaR/SBDD) generating licensing revenue from global pharma partners. Similar platform-tech licensing model with comparable Japan listing history.

TypeBroad incumbent
Description

Japan's largest pharmaceutical company and LTT's landlord through Shonan iPark affiliation. Established incumbent with DDS interest and partnership potential as a licensee for LTT's pipeline assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LTT Bio-Pharma

Pharmaceutical Drug Developmentltt.co.jp

LTT Bio-Pharma is a Tokyo-based drug discovery bio-venture that uses proprietary Drug Repositioning and Drug Delivery System (DDS) technologies, including a 1,000+ approved drug library and world-first lecithinization and stealth-nanoparticle platforms, to develop and out-license pipeline assets to pharmaceutical partners in Japan, China, and increasingly Europe.

What LTT Bio-Pharma does

LTT Bio-Pharma Co., Ltd. (株式会社LTTバイオファーマ) is a privately held Japanese drug discovery bio-venture founded in 1988 (spun off into its current legal form in 2003), headquartered in Tokyo with a research center at Shonan Health Innovation Park in Fujisawa. The company operates two proprietary technology platforms: Drug Repositioning (DR), supported by a proprietary library of 1,000+ approved drugs used for indication screening, and Drug Delivery System (DDS), encompassing world-first lecithinization technology (commercialized as PC-SOD), world-first stealth-type nanoparticles combining targeting and sustained release, and an established lipid emulsion DDS platform. Its marketed product family includes lipo-PGE1, lipo-NSAID, liposteroid, and transdermal steroid formulations licensed to major Japanese pharmaceutical partners and, in China, to Beijing Tide Pharmaceutical.

The company's pipeline of approximately 14 development candidates spans PC-SOD for CIPN/ARDS/myocardial infarction, LT-5001 in Phase III with Nobelpharma for trigeminal neuralgia, stealth-nanoparticle programs (Nano-PGE1, Nano-PGI2 derivative), and multiple DR-derived assets (LT-3001/3002/4001/4002/4010/4012) for COPD, dry eye, pulmonary fibrosis, and COVID-19 indications. Revenue is generated through four streams: licensing royalties and milestone payments (including from Beijing Tide for China and CKD for Korea), contract research and DR/DDS consultation services, joint development arrangements (e.g., LT-5001 with Nobelpharma; PC-SOD with Alfresa), and dividend income from the >11% equity stake in Beijing Tide Pharmaceutical. Distribution is entirely virtual: products are manufactured and commercialized by licensing partners.

LTT Bio-Pharma serves three primary customer segments: pharmaceutical companies seeking DR/DDS expertise and pipeline assets, Japanese academic institutions supported via DR Grant and PC-SOD Grant programs, and Japanese/Chinese medical companies needing cross-border licensing bridge services. The company maintains a capital and business alliance with Sino Biopharm (China's largest pharma group, 17%+ stake acquired via 2021 tender offer, renewed 2025) and operates a complex cross-shareholding with Beijing Tide Pharmaceutical (19%+ of LTT; 11%+ of Beijing Tide held by LTT). The company was listed on TSE Mothers in 2004, delisted in 2011, and is currently pursuing re-listing while reporting FY2025 net sales of ¥61.4 million against ¥5.26 billion in net assets and a 94.1% equity ratio.

LTT Bio-Pharma firmographics

Firmographics
Name
LTT Bio-Pharma
Legal name
株式会社LTTバイオファーマ
Website
https://ltt.co.jp
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
LTT Bio-Pharma is a Tokyo-based drug discovery bio-venture that uses proprietary Drug Repositioning and Drug Delivery System (DDS) technologies, including a 1,000+ approved drug library and world-first lecithinization and stealth-nanoparticle platforms, to develop and out-license pipeline assets to pharmaceutical partners in Japan, China, and increasingly Europe.
Ownership category
akta.pro rank

LTT Bio-Pharma industry classification

Industry
Product category
Pharmaceutical Drug Development
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Drug repositioning
  • Drug delivery systems
  • Pharmaceutical licensing
  • Clinical drug development
  • Lipid emulsion formulations

Where LTT Bio-Pharma is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

LTT Bio-Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing Revenue: Revenue from licensing out pipeline assets (drug candidates at various development stages) to pharmaceutical companies. Some pipelines have progressed to Phase II clinical trials and are available for out-licensing. Also includes licensing fees from Beijing Tide Pharmaceutical for PC-SOD and AS-013 for the Chinese market, and CKD for Korean market.
  2. Contract Research & Consultation: Revenue from DR (drug repositioning) screening services, intellectual property consulting, and clinical trial bridging support provided to pharmaceutical companies and academic institutions. Includes DR grants to academia with funding up to 3 million yen per project.
  3. Joint Development Revenue: Revenue from joint development arrangements where the company collaborates with partners on drug development, sharing costs and profits. Notable joint development with Nobelpharma Co., Ltd. since 2018 on LT-5001, and Alfresa Holdings on PC-SOD.
  4. Dividend Income: Dividend income from equity stakes in affiliated companies, primarily from Beijing Tide Pharmaceutical Co., Ltd. where LTT holds over 11% ownership.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractDR Grant - Academic Research Support
OtherMulti-year contractPC-SOD Grant - Academic Research Support

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

LTT Bio-Pharma product offering

Product offering

Core offering

LTT Bio-Pharma is a Tokyo-based drug discovery bio-venture that researches, develops, and commercializes pharmaceutical products using two proprietary technology platforms: Drug Repositioning (DR) and Drug Delivery Systems (DDS). The company has successfully launched multiple DDS-formulated products (Lipo-PGE1, Lipo-NSAID, liposteroid, and transdermal steroid formulations) through licensing partnerships with major Japanese and Chinese pharmaceutical companies, and maintains a pipeline of 14 drug candidates in clinical and preclinical development including PC-SOD and LT-5001.

Product overview

LTT Bio-Pharma is a drug discovery bio-venture company that has developed a portfolio of pharmaceutical products utilizing two core technology platforms: Drug Repositioning (DR) and Drug Delivery Systems (DDS). The company has successfully launched multiple DDS-based formulations including lipo-PGE1 products (Palux, Riple, Kaishi), lipo-steroids (Rimetasone, Farnesone, Farenerat, Haloart), and lipo-NSAIDs (Ropion, Kaifeng). Their pipeline includes PC-SOD (lecithinized SOD1) for CIPN and other indications, stealth-type nanoparticle products (NanoPGE1, Nano PGI2), and various DR-derived candidates (LT-3001, LT-3002, LT-4001, LT-4002, LT-4010, LT-4012, LT-5001). The company operates through collaborative R&D models with academia and pharmaceutical partners, leveraging their proprietary approved drug library and DDS technologies.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • PC-SOD Phase II clinical trials showed efficacy in CIPN (chemotherapy-induced peripheral neuropathy) with statistical significance
  • +2 more outcomes

Companies that use LTT Bio-Pharma

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

LTT Bio-Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

LTT Bio-Pharma partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Beijing Tide Pharmaceutical Co., Ltd.coreStrategic or Co-development Partner · 10 February 2009Joint venture established in 1995 between LTT and China-Japan Friendship Hospital. LTT provides DDS technology and IP; Beijing Tide manufactures and sells DDS drugs in China. LTT holds 11%+ equity stake; Beijing Tide holds 19%+ of LTT shares. Joint R&D on PC-SOD and other pipelines. LTT acts as Beijing Tide's window for Japanese partnerships.
  • Nobelpharma Co., Ltd.coreStrategic or Co-development PartnerJoint development agreement since 2018 for LT-5001 drug (drug repositioning for existing drug). Companies jointly conduct clinical trials and share profits. Nobelpharma contributes high development success rate and regulatory expertise; LTT contributes DR technology. Phase III clinical trials ongoing for trigeminal neuralgia.
  • Alfresa Holdings CorporationcoreStrategic or Co-development PartnerPC-SOD joint development agreement concluded in 2025. Alfresa contributes to PC-SOD development for CIPN (chemotherapy-induced peripheral neuropathy) prevention/treatment.
  • Kansai Medical UniversityminorStrategic or Co-development PartnerJoint research agreement signed April 2026 for drug discovery collaboration. Part of LTT's strategy to engage with academic institutions for pipeline development.
  • Nihon University (College of Engineering)minorStrategic or Co-development PartnerContract research partner for DDS development. Collaborative research on stealth-type nanoparticle development using PLA (polylactic acid) technology.
  • Musashino University (Faculty of Pharmacy)minorStrategic or Co-development PartnerCollaborative DR research for pulmonary fibrosis treatment. Jointly screened approved drug library with LTT to discover LT-4010 for idiopathic pulmonary fibrosis.
  • Shujitsu University (Faculty of Pharmacy)minorStrategic or Co-development PartnerContract research partner for drug development activities.
  • Aska Pharmaceutical Holdings Co., Ltd.minorOthersDR consulting service agreement concluded 2021 for drug repositioning expertise and guidance.
  • ChongKunDang Pharm Corp (CKD)minorOEM/ Whitelabel/ Licensing PartnerLicensed PC-SOD (inhalation formulation) for entire Korean territory in 2011.
  • EA Pharma Co., Ltd.minorOEM/ Whitelabel/ Licensing PartnerLicense agreement signed 2015 for pipeline LT-4004.

Scale indicators6 records

Recent moves12 records

Expansion highlights5 records

LTT Bio-Pharma competitors and assessment

Company assessment

Direct peers

  • NanoCarrier: Japanese bio-venture specializing in micellar nanoparticle drug delivery technology for nucleic acid drugs and other therapeutics. Direct comparable as a small-cap Japanese DDS-focused biotech with similar licensing model.
  • SymBio Pharmaceuticals: Japanese specialty pharmaceutical company focused on niche therapeutic areas with in-licensing and co-development model. Similar size and venture-stage profile with comparable revenue/development stage.
  • AnGes: Japanese bio-venture developing novel biologics and gene therapies, with similar late-stage clinical assets and licensing-driven business model. Comparable venture-stage bio-pharma with multiple pipeline candidates.

Broad incumbents

  • JCR Pharmaceuticals: Japanese biopharmaceutical company with proprietary drug delivery technologies including J-Brain Cargo platform for CNS drug delivery. Larger established player with overlapping DDS expertise but broader portfolio.
  • Mochida Pharmaceutical: Japanese specialty pharmaceutical company with focus on specialty pharma, regenerative medicine, and novel drug formulations. Larger incumbent with overlap in specialty pharmaceutical development.
  • Takeda Pharmaceutical: Japan's largest pharmaceutical company and LTT's landlord through Shonan iPark affiliation. Established incumbent with DDS interest and partnership potential as a licensee for LTT's pipeline assets.

Emerging players

  • PeptiDream: Japanese bio-pharma with proprietary peptide discovery platform serving global pharma partners via licensing deals. Similar platform-based business model with global pharma licensing as core revenue driver.
  • Sosei Group Corporation: Japanese biotech with proprietary drug discovery platform (StaR/SBDD) generating licensing revenue from global pharma partners. Similar platform-tech licensing model with comparable Japan listing history.

Others

  • EPS Holdings: Japanese CRO and pharma services provider. Not a direct competitor but comparable as a Japan-listed pharma services/development company serving similar pharmaceutical customers.
  • CMIC Holdings: Japan's largest CRO providing drug development services including clinical trial support. Comparable as Japanese pharma services/development ecosystem participant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

LTT Bio-Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LTT Bio-Pharma leadership team

Management profile

Number of profiles

Profiles3 records

LTT Bio-Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LTT Bio-Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LTT Bio-Pharma

What does LTT Bio-Pharma do?

LTT Bio-Pharma is a Tokyo-based drug discovery bio-venture that researches, develops, and commercializes pharmaceutical products using two proprietary technology platforms: Drug Repositioning (DR) and Drug Delivery Systems (DDS). The company has successfully launched multiple DDS-formulated products (Lipo-PGE1, Lipo-NSAID, liposteroid, and transdermal steroid formulations) through licensing partnerships with major Japanese and Chinese pharmaceutical companies, and maintains a pipeline of 14 drug candidates in clinical and preclinical development including PC-SOD and LT-5001.

Is LTT Bio-Pharma a public or private company?

LTT Bio-Pharma is a private company. It is classified as corporate owned and is currently operating.

When was LTT Bio-Pharma founded?

LTT Bio-Pharma was founded in 2003. It employs 11 to 50 people.

Where is LTT Bio-Pharma based?

LTT Bio-Pharma is headquartered in Tokyo, Japan, in the Asia region.

How does LTT Bio-Pharma make money?

Four revenue lines are on record. Licensing Revenue is the primary driver. The others are contract Research & Consultation, joint Development Revenue and dividend Income.

Who are LTT Bio-Pharma's main competitors?

Direct peers on record are NanoCarrier, SymBio Pharmaceuticals and AnGes. Broad incumbents are JCR Pharmaceuticals, Mochida Pharmaceutical and Takeda Pharmaceutical. Emerging players are PeptiDream and Sosei Group Corporation. Others are EPS Holdings and CMIC Holdings.

Does LTT Bio-Pharma have an API?

No public API is recorded for LTT Bio-Pharma.

What industry is LTT Bio-Pharma in?

LTT Bio-Pharma's product category is Pharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals